Table 1.
Demographics and clinical data.
| Patients | n (%) | |
|---|---|---|
| Age (median range) | 60.5 years to 4–83 years | 64 * |
| Age (at the time of first surgery) | <55 | 27 (42.2%) |
| ≥55 | 37 (57.8%) | |
| Sex | Male | 21 (32.8%) |
| Female | 43 (67.2%) | |
| Ratio (M/F) | 0.48 | |
| Side of tumour | Right | 32 (50%) |
| Left | 31 (48.4%) | |
| Bilateral | 1 (1.6%) | |
| Lobe | Superficial | 50 (78.1%) |
| Deep | 6 (9.4%) | |
| Both | 9 (12.5%) | |
| Preoperative work-up | US | 42 (65.6%) |
| CT | 16 (25%) | |
| MRI | 57 (89%) | |
| FNAC | 28 (43.7%) | |
| Biopsy | 7 (10.9%) | |
| Surgical treatment | Parotidectomy I | 0 (0%) |
| (according to Quer’s classification) | Parotidectomy I-II | 32 (49.2%) |
| Parotidectomy I-II-III | 14 (21.5%) | |
| Parotidectomy I-IV | 9 (13.8%) | |
| Parotidectomy I-IV (VII) | 10 (15.5%) | |
| Reconstructive surgery | Radial forearm free flap | 1 (1.5%) |
| Rectus abdominis free flap | 1 (1.5%) | |
| Anterolateral thigh free flap | 1 (1.5%) | |
| No | 62 (95.4%) | |
| Clinical nerve involvement (CNI) | Yes | 3 (4.6%) |
| No | 54 (83%) | |
| Facial nerve resection | Partial | 10 (15.5%) |
| Complete | 1 (1.5%) | |
| House–Brackmann (>6 month) | I | 48 (75%) |
| II | 8 (12.5%) | |
| III | 5 (7.8%) | |
| IV | 2 (3.1%) | |
| V | 1 (1.6%) | |
| VI | 0 (0%) | |
| Neck dissection | No | 46 (70.8%) |
| Yes | 19 (29.2%) | |
| Concomitant | 13 | |
| Delayed | 3 | |
| Neck recurrence | 3 | |
| Tumour’s size | ≤2 cm | 23 (35.4%) |
| >2–≤4 cm | 37 (56.9%) | |
| >4 cm | 5 (7.7%) | |
| Histological diagnosis | Acinic cell carcinoma | 16 (24.6%) |
| Mucoepidermoid carcinoma | 13 (20%) | |
| Carcinoma ex pleomorphic adenoma | 8 (12.3%) | |
| Adenoid cystic carcinoma | 8 (12.3%) | |
| Myoepithelial carcinoma | 4 (6.2%) | |
| Secretory carcinoma | 3 (4.5%) | |
| Primitive squamous cell carcinoma | 3 (4.5%) | |
| Oncocytic carcinoma | 3 (4.5%) | |
| Adenocarcinoma | 2 (3%) | |
| Salivary duct carcinoma | 2 (3%) | |
| High grade carcinoma | 2 (3%) | |
| Undifferentiated carcinoma | 1 (1.5%) | |
| pT stage | pT1 | 17 (26.1%) |
| pT2 | 26 (40.0%) | |
| pT3 | 13 (20.0%) | |
| pT4a + pT4b | 9 (13.9%) | |
| pN stage | pN0 | 54 (83.1%) |
| pN+ | 11 (16.9%) | |
| ENE+ | 5/11 (45.4%) | |
| Stage | I | 17 (26.1%) |
| II | 22 (33.8%) | |
| III | 10 (15.4%) | |
| IVa + IVb | 16 (24.7%) | |
| Status of margins | R0 | 43 (66.2%) |
| R close (<5 mm) | 13 (20%) | |
| R1 | 9 (13.8%) | |
| Adjuvant treatment | Radiotherapy | 30 (46.9%) |
| Chemoradiotherapy | 2 (3.1%) | |
| No | 32 (50%) | |
| Relapse | No | 53 (81.5%) |
| N recurrence | 3 (3%) | |
| Distant metastasis | 7 (10.8%) | |
| Persistence | T | 1 (1.5%) |
* Sixty-four patients, 65 lesions.